Literature DB >> 21196198

Lymphangiogenesis and cancer metastasis.

Mahir A A Al-Rawi1, Wen G Jiang.   

Abstract

Lymphangiogenesis remains a fascinating biological process that plays a crucial role in both normal tissue development and several lymphatic diseases. The last few years have witnessed a rapid progression in understanding the development and regulation of the lymphatic system which provided insight on several pathological processes including cancer lymphatic metastasis. Lymphatic vasculature serves as a major route for tumour metastasis. The dissemination of malignant cells to the regional lymph nodes is an early step in the progression of many solid tumours and is an important determinant of staging and prognosis. Lymphangiogenesis is thought to play a pivotal role for cancer cells to metastasis to the regional lymph nodes. Several human solid tumours are now considered to be lymphangiogenic i.e. they have the ability to induce their own lymphatic vessels to establish metastasis. Hence, targeting lymphangiogenesis by developing anti-lymphangiogenic agents might constitute a novel way to prevent lymphatic progression in some tumours. Here, we have reviewed the development of the lymphatic system, the regulation of lymphangiogenesis and explored its relation to several human cancers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21196198     DOI: 10.2741/3715

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  12 in total

1.  Treating breast cancer metastasis with cabazitaxel-loaded polymeric micelles.

Authors:  Tao Zhong; Bin He; Hai-Qiang Cao; Tao Tan; Hai-Yan Hu; Ya-Ping Li; Zhi-Wen Zhang
Journal:  Acta Pharmacol Sin       Date:  2017-05-01       Impact factor: 6.150

2.  Increased Expression of Gremlin1 Promotes Proliferation and Epithelial Mesenchymal Transition in Gastric Cancer Cells and Correlates With Poor Prognosis of Patients With Gastric Cancer.

Authors:  Zhiwei Sun; Shuo Cai; Chang Liu; Yuxin Cui; Jiafu Ji; Wen G Jiang; Lin Ye
Journal:  Cancer Genomics Proteomics       Date:  2020 Jan-Feb       Impact factor: 4.069

3.  The Amazing Power of Cancer Cells to Recapitulate Extraembryonic Functions: The Cuckoo's Tricks.

Authors:  Jose-Ignacio Arias; Maria-Angeles Aller; Isabel Prieto; Ana Arias; Zoe de Julian; Heping Yang; Jaime Arias
Journal:  J Oncol       Date:  2011-09-28       Impact factor: 4.375

4.  Th2 Cytokines IL-4, IL-13, and IL-10 Promote Differentiation of Pro-Lymphatic Progenitors Derived from Bone Marrow Myeloid Precursors.

Authors:  Maria Espinosa Gonzalez; Lisa Volk-Draper; Nihit Bhattarai; Andrew Wilber; Sophia Ran
Journal:  Stem Cells Dev       Date:  2022-05-23       Impact factor: 4.390

5.  Interleukin-8: A potent promoter of human lymphatic endothelial cell growth in gastric cancer.

Authors:  Jun Shi; Yong-Jin Li; Bing Yan; Pin-Kang Wei
Journal:  Oncol Rep       Date:  2015-04-17       Impact factor: 3.906

Review 6.  Angiogenesis-related pathways in the pathogenesis of ovarian cancer.

Authors:  Nikos G Gavalas; Michalis Liontos; Sofia-Paraskevi Trachana; Tina Bagratuni; Calliope Arapinis; Christine Liacos; Meletios A Dimopoulos; Aristotle Bamias
Journal:  Int J Mol Sci       Date:  2013-07-30       Impact factor: 5.923

7.  Inhibition of lymphangiogenesis of endothelial progenitor cells with VEGFR-3 siRNA delivered with PEI-alginate nanoparticles.

Authors:  Ting Li; Guo-dong Wang; Yu-zhen Tan; Hai-jie Wang
Journal:  Int J Biol Sci       Date:  2014-01-18       Impact factor: 6.580

8.  Extracellular matrix protein 1 is correlated to carcinogenesis and lymphatic metastasis of human gastric cancer.

Authors:  Qiuwan Wu; Xiaohong Li; Haiyan Yang; Chuanhui Lu; Jun You; Zhiming Zhang
Journal:  World J Surg Oncol       Date:  2014-04-29       Impact factor: 2.754

Review 9.  The role of lymphangiogenesis and angiogenesis in tumor metastasis.

Authors:  Roman Paduch
Journal:  Cell Oncol (Dordr)       Date:  2016-04-28       Impact factor: 6.730

10.  Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib.

Authors:  Tong Lin; Lan Gong
Journal:  Drug Des Devel Ther       Date:  2017-04-05       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.